Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5C2 | P49902 | 2/20 | 0.67 |
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23123 | 0.92 | BRD4 (0.64) | NT5C2BRD4NT5ENPC1RAB9A | |
| SCHEMBL8381773 | 0.91 | BRD4 (0.63) | NT5C2BRD4NT5ENPC1RAB9A | |
| SCHEMBL16619108 | 0.90 | NT5C2 (0.69) | NT5C2BRD4NT5EEGFRAURKB | |
| SCHEMBL6463473 | 0.88 | BRD4 (0.60) | NT5C2BRD4NT5EADORA3ADORA2A | |
| SCHEMBL2623133 | 0.84 | BRD4 (0.49) | NT5C2BRD4MEN1NPC1RAB9A | |
| SCHEMBL16619414 | 0.82 | NPC1 (0.48) | NT5C2BRD4NT5EMEN1NPC1 | |
| SCHEMBL18066325 | 0.82 | CHRNB2 (0.50) | NT5C2BRD4NT5EPOLB | |
| SCHEMBL14192926 | 0.82 | CSF1R (0.51) | NT5C2BRD4NT5ENPC1RAB9A | |
| SCHEMBL9230078 | 0.81 | BRD4 (0.68) | BRD4ADORA3MEN1NPC1RAB9A | |
| SCHEMBL27714082 | 0.80 | BRD4 (0.46) | NT5C2BRD4NT5EEGFRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | claimed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | claimed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | claimed |
| EP-3052500-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Centre National De La Recherche Scientifique (FR) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049447-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-04-09 | — | — | WO | claimed |
| EP-3052500-B1 | INHIBITORS OF 5'-NUCLEOTIDASES AND THERAPEUTIC USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2018-01-03 | — | — | EP | disclosed |
| US-9783541-B2 | 5′-nucleotidase inhibitors and therapeutic uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-09-22 | — | — | US | disclosed |
| EP-3052500-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | Centre National De La Recherche Scientifique (FR) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049447-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272643-A1 | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF | NTPCR, NT5E, PNP | NT5C2 5/4885BRD4 1545/4885NT5E 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.